Multiple Myeloma Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
P
MagnetisMM-9: Study of Elranatamab (PF-06863135) Monotherapy in Participants With Relapsed/Refractory Multiple Myeloma
Recruiting
  • Multiple Myeloma
  • Austin, Texas
  • +3 more
2021-10-12
Oct 12, 2021
T
A Study of Real Life Treatment for Multiple Myeloma (MM)
Not yet recruiting
  • Multiple Myeloma
    • Astrakhan, Russian Federation
    • +13 more
    2021-10-14
    Oct 14, 2021
    P
    MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb
    Recruiting
    • Multiple Myeloma
    • Elranatamab (PF-06863135)
    • Beverly Hills, California
    • +85 more
    2021-10-14
    Oct 14, 2021
    J
    A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma
    Active, not recruiting
    Has Results
    • Multiple Myeloma
    • Antwerpen, Belgium
    • +12 more
    2021-10-14
    Oct 14, 2021
    J
    A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma
    Active, not recruiting
    Has Results
    • Multiple Myeloma
    • Dara SC
    • Dara IV
    • Boston, Massachusetts
    • +146 more
    2021-10-14
    Oct 14, 2021
    J
    A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
    Recruiting
    • Multiple Myeloma
    • Birmingham, Alabama
    • +79 more
    2021-10-14
    Oct 14, 2021
    J
    A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma
    Recruiting
    • Multiple Myeloma
    • Birmingham, Alabama
    • +100 more
    2021-10-14
    Oct 14, 2021
    N
    Natural Killer Cells and Bortezomib to Treat Cancer - 2021
    Completed
    • Chronic Myeloid Leukemia (CML)
    • +4 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center, 9000 Rockville Pi
    2021-10-14
    Oct 14, 2021
    N
    BCMA-directed CAR-T Cell Therapy in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
    Recruiting
    • Multiple Myeloma
    • PHE885
    • Chicago, Illinois
    • +3 more
    2021-10-14
    Oct 14, 2021
    J
    A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)
    Active, not recruiting
    • Multiple Myeloma
    • Beijing, China
    • +43 more
    2021-10-14
    Oct 14, 2021
    J
    A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
    Recruiting
    • Multiple Myeloma
    • San Francisco, California
    • +123 more
    2021-10-14
    Oct 14, 2021
    J
    A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma
    Active, not recruiting
    • Multiple Myeloma
    • Beijing, China
    • +26 more
    2021-10-14
    Oct 14, 2021
    R
    First in Human (FIH) Study of REGN5458 in Patients With Relapsed or Refractory Multiple Myeloma
    Recruiting
    • Multiple Myeloma
    • Miami, Florida
    • +14 more
    2021-10-07
    Oct 7, 2021
    J
    A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
    Active, not recruiting
    • Multiple Myeloma
    • Whittier, California
    • +113 more
    2021-10-14
    Oct 14, 2021
    J
    A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent
    Recruiting
    • Multiple Myeloma
    • Ahmedabad, India
    • +19 more
    2021-10-14
    Oct 14, 2021
    H
    Multiple Myeloma Molecular Monitoring Study
    Recruiting
    • Multiple Myeloma
      • Calgary, Alberta, Canada
      • +12 more
      2021-10-14
      Oct 14, 2021
      N
      Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
      Not yet recruiting
      • Multiple Myeloma
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      2021-10-14
      Oct 14, 2021
      P
      MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
      Recruiting
      • Multiple Myeloma
      • Seoul, Seoul-teukbyeolsi [seoul], Korea, Republic of
      • +3 more
      2021-10-14
      Oct 14, 2021
      J
      A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment
      Active, not recruiting
      • Multiple Myeloma
      • No intervention
      • Tucson, Arizona
      • +85 more
      2021-10-14
      Oct 14, 2021
      J
      A Registry Study of Participants With Multiple Myeloma in Latin America
      Active, not recruiting
      • Multiple Myeloma
      • No intervention
      • Buenos Aires, Argentina
      • +22 more
      2021-10-14
      Oct 14, 2021
      S
      Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients
      Active, not recruiting
      • Multiple Myeloma
      • Isatuximab SAR650984
      • Nagoya-shi, Aichi, Japan
      • +12 more
      2021-10-14
      Oct 14, 2021
      J
      Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma
      Active, not recruiting
      Has Results
      • Multiple Myeloma
      • Daratumumab IV
      • +3 more
      • Birmingham, Alabama
      • +211 more
      2021-10-14
      Oct 14, 2021
      M
      Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma
      Not yet recruiting
      • Multiple Myeloma
      • Belantamab mafodotin
      • Houston, Texas
        M D Anderson Cancer Center
      2021-10-13
      Oct 13, 2021
      U
      A New Study Evaluating the Activity of Modular CAR T for mYeloma
      Not yet recruiting
      • Multiple Myeloma
      • BCMA CAR T cells
      • BCMA/CD19 CAR T cells
      • (no location specified)
      2021-10-05
      Oct 5, 2021
      Z
      Quality of Life in Patients With Multiple Myeloma-validation Study - 2021
      Terminated
      • Multiple Myeloma
      • Myeloma Patient Outcome Scale (MyPOS)
      • Münsterlingen, Thurgau, Switzerland
      • +2 more
      2021-10-05
      Oct 5, 2021